# BR55 in Characterization of Ovarian Lesions

> **NCT03493464** · PHASE2 · TERMINATED · sponsor: **Bracco Diagnostics, Inc** · enrollment: 14 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** BR55

## Key facts

- **NCT ID:** NCT03493464
- **Lead sponsor:** Bracco Diagnostics, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-12-13
- **Primary completion:** 2021-04-15
- **Final completion:** 2021-07-31
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Sponsor decision; expiration of available study agent due to long recruitment timeline.
- **Last updated:** 2024-09-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493464, "BR55 in Characterization of Ovarian Lesions". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03493464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*